Cover Image
市場調查報告書

Delenex Therapeutics AG - 產品平台分析

Delenex Therapeutics AG - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 256006
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
Delenex Therapeutics AG - 產品平台分析 Delenex Therapeutics AG - Product Pipeline Review - 2016
出版日期: 2016年02月29日 內容資訊: 英文 37 Pages
簡介

Delenex Therapeutics AG是總公司設立於瑞士的生物製藥企業,正在進行以癌症,皮膚疾病為中心的抗體治療藥之開發與製造。正在利用實現了scFv抗體片段等多種抗體開發的PENTRA技術平台來開發新產品。

本報告提供Delenex Therapeutics AG的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Delenex Therapeutics AG 基本資料

  • Delenex Therapeutics AG 概要
  • 主要資訊
  • 企業資料

Delenex Therapeutics AG :R&D概要

  • 主要的治療範圍

Delenex Therapeutics AG :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Delenex Therapeutics AG :開發中產品概況

  • 後期階段產品開發中產品
    • 第Ⅲ期的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第Ⅱ期的產品/聯合治療模式
    • 第Ⅰ期的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Delenex Therapeutics AG :藥物簡介

  • DLX-1008
  • DLX-105
  • DLX-2323
  • DLX-2681
  • DLX-2751
  • DLX-2882
  • DLX-2907
  • DLX-2909
  • DLX-2201
  • Monoclonal Antibody Conjugate for Oncology and Inflammation
  • Monoclonal Antibody for Oncology and Inflammation
  • Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis

Delenex Therapeutics AG :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Delenex Therapeutics AG :開發暫停中的計劃

Delenex Therapeutics AG :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07967CDB

Summary

Global Markets Direct's, 'Delenex Therapeutics AG - Product Pipeline Review - 2016', provides an overview of the Delenex Therapeutics AG's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Delenex Therapeutics AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Delenex Therapeutics AG
  • The report provides overview of Delenex Therapeutics AG including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Delenex Therapeutics AG's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Delenex Therapeutics AG's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Delenex Therapeutics AG's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Delenex Therapeutics AG
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Delenex Therapeutics AG's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Delenex Therapeutics AG Snapshot
    • Delenex Therapeutics AG Overview
    • Key Information
    • Key Facts
  • Delenex Therapeutics AG - Research and Development Overview
    • Key Therapeutic Areas
  • Delenex Therapeutics AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Delenex Therapeutics AG - Pipeline Products Glance
    • Delenex Therapeutics AG - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Delenex Therapeutics AG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Delenex Therapeutics AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Delenex Therapeutics AG - Drug Profiles
    • DLX-1008
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DLX-105
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DLX-2323
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DLX-2681
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DLX-2751
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DLX-2882
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DLX-2907
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DLX-2909
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DLX-2201
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate for Oncology and Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Oncology and Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Delenex Therapeutics AG - Pipeline Analysis
    • Delenex Therapeutics AG - Pipeline Products by Target
    • Delenex Therapeutics AG - Pipeline Products by Route of Administration
    • Delenex Therapeutics AG - Pipeline Products by Molecule Type
    • Delenex Therapeutics AG - Pipeline Products by Mechanism of Action
  • Delenex Therapeutics AG - Recent Pipeline Updates
  • Delenex Therapeutics AG - Dormant Projects
  • Delenex Therapeutics AG - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Delenex Therapeutics AG, Key Information
  • Delenex Therapeutics AG, Key Facts
  • Delenex Therapeutics AG - Pipeline by Indication, 2016
  • Delenex Therapeutics AG - Pipeline by Stage of Development, 2016
  • Delenex Therapeutics AG - Monotherapy Products in Pipeline, 2016
  • Delenex Therapeutics AG - Phase III, 2016
  • Delenex Therapeutics AG - Phase II, 2016
  • Delenex Therapeutics AG - Phase I, 2016
  • Delenex Therapeutics AG - Preclinical, 2016
  • Delenex Therapeutics AG - Discovery, 2016
  • Delenex Therapeutics AG - Pipeline by Target, 2016
  • Delenex Therapeutics AG - Pipeline by Route of Administration, 2016
  • Delenex Therapeutics AG - Pipeline by Molecule Type, 2016
  • Delenex Therapeutics AG - Pipeline Products by Mechanism of Action, 2016
  • Delenex Therapeutics AG - Recent Pipeline Updates, 2016
  • Delenex Therapeutics AG - Dormant Developmental Projects,2016

List of Figures

  • Delenex Therapeutics AG - Pipeline by Top 10 Indication, 2016
  • Delenex Therapeutics AG - Pipeline by Stage of Development, 2016
  • Delenex Therapeutics AG - Monotherapy Products in Pipeline, 2016
  • Delenex Therapeutics AG - Pipeline by Target, 2016
  • Delenex Therapeutics AG - Pipeline by Route of Administration, 2016
  • Delenex Therapeutics AG - Pipeline by Molecule Type, 2016
  • Delenex Therapeutics AG - Pipeline Products by Mechanism of Action, 2016
Back to Top